|
시장보고서
상품코드
2008075
혈당강하제 시장 : 약물 종류별, 투여 경로별, 유통 채널별, 지역별Hypoglycemic Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
혈당강하제 시장은 2026년에 9억 520만 달러로 추정되며, 2033년까지 12억 7,060만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 9.6%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 9억 520만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 9.60% | 예측 금액(2033년) | 12억 7,060만 달러 |
저혈당이란 혈당(포도당)이 기준치 이하로 떨어진 상태를 말합니다. 포도당은 우리 몸의 주요 에너지원입니다. 저혈당은 종종 당뇨병 치료와 관련이 있습니다. 저혈당은 혈중 포도당 농도가 설정치, 즉 4mmol/L(72mg/dL) 이하로 떨어졌을 때 발생합니다. 저혈당에 따른 증상으로는 발한, 피로감, 어지러움, 쇠약감, 시야 흐림 등을 들 수 있습니다. 저혈당은 혈당 측정기를 이용하여 혈당을 측정함으로써 감지할 수 있습니다. 혈당 수치가 4.0 mmol/L 이하로 떨어지면 저혈당 상태인 것으로 간주합니다.
시장 역학
당뇨병 유병률의 증가는 세계 혈당강하제 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 미국당뇨병협회가 2022년 7월 28일 발표한 기사에 따르면, 2019년 미국인 3,730만 명, 즉 인구의 11.3%가 당뇨병을 앓고 있다고 합니다. 약 190만 명의 미국인이 1형 당뇨병을 앓고 있으며, 그 중 약 24만 4,000명이 소아 및 청소년입니다. 이 소식통에 따르면, 매년 140만 명의 미국인이 당뇨병 진단을 받고 있습니다. 또한 2014년부터 2015년까지 젊은 층의 연간 당뇨병 발병 건수는 1형 당뇨병 1만 8,200명, 2형 당뇨병 5,800명으로 추정되고 있습니다.
규제 당국의 의약품 승인 건수 증가가 세계 혈당강하제 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 2020년 12월 전문 제약사 Amphastar Pharmaceuticals, Inc.는 미국 식품의약국(FDA)이 자사의 '글루카곤 주사제 응급 키트(1mg)'에 대한 간이신약허가신청(ANDA)을 승인했다고 발표했습니다. 글루카곤은 중증 저혈당증 치료에 사용되며, 진단 보조제로도 사용됩니다.
본 보고서의 주요 특징
- 세계의 혈당강하제 시장에 대해 조사분석했으며, 2025년을 기준 연도로 하여 예측 기간(2026-2033년)의 시장 규모와 CAGR을 조사하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 세계 혈당 강하제 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 작성되었습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 종류 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 저혈당 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 혈당강하제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 혈당강하제 시장 : 약물 종류별(2026-2033년)
제5장 세계의 혈당강하제 시장 : 투여 경로별(2026-2033년)
제6장 세계의 혈당강하제 시장 : 유통 채널별(2026-2033년)
제7장 세계의 혈당강하제 시장 : 지역별(2026-2033년)
제8장 경쟁 구도
제9장 섹션
KSM 26.04.30Hypoglycemic Drugs Market is estimated to be valued at USD 905.2 Mn in 2026 and is expected to reach USD 1,270.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 905.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.60% | 2033 Value Projection: | USD 1,270.6 Mn |
Hypoglycemia is a condition in which blood sugar (glucose) level is lower than the standard range. Glucose is the main energy soiurce for the body. Hypoglycemia is often related to diabetes treatment. Hypoglycemia occurs when the level of glucose present in the blood falls below a set point, i.e., below 4 mmol/L (72mg/dL). The symptoms associated with Hypogyclemia are, sweating, fatigue, feeling dizzy, feeling weak, blurred vision, and others. Hypoglycemia is detected by measuring blood sugar levels with a glucose meter. Any blood glucose level below 4.0 mmol/L indicates that the individual has hypoglycemia.
Market Dynamics
Increasing prevalence of diabetes is expected to drive growth of the global hypoglycemic drugs market. For instance, according to an article published by American Diabetes Association on 28 July 2022, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents. 1.4 million Americans are diagnosed with diabetes every year.according to same soruce, In 2014-2015, the annual incidence of diagnosed diabetes in youth was estimated at 18,200 with type 1 diabetes and 5,800 with type 2 diabetes.
Increasing number of drug approvals from regulatory bodies is expected to drive growth of the global hypoglycemic drugs market. For instance, in December 2020, Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid.
Key features of the study
- This report provides an in-depth analysis of the global hypoglycemic drugs market, provides market size (USD Mn), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global hypoglycemic drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceuticals NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global hypoglycemic drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global hypoglycemic drugs market
Market Segmentation
- Global Hypoglycemic Drugs Market, By Drug Class
- Sulphonylureas
- Biguanides
- Alpha-glucosidase inhibitors
- Thiazolidinediones (Glitazones)
- Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Glucagon
- Global Hypoglycemic Drugs Market, By Route of Administration
- Oral
- Injectable
- Nasal
- Global Hypoglycemic Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hypoglycemic Drugs Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Eli Lilly & Company,
- Boehringer Ingelheim GmbH,
- Vistin Pharma AS,
- Janssen Pharmaceutica NV,
- Sanofi, Astellas Pharma Inc.,
- AstraZeneca plc.,
- Merck & Co., Inc.,
- Novartis AG.,
- Novo Nordisk A/S,
- Teva Pharmaceuticals Pvt Ltd.,
- Sun Pharmaceutical Industries Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- List of Distributors
- Key Developments
- PEST Analysis
- Regulatory Scenario
- New Product Launch/ Approval
- Acquisition and Partnership Scenario
- Market Trends
4. Global Hypoglycemic Drugs Market, By Drug Class, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
- Sulphonylureas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Biguanides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Alpha-glucosidase inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Thiazolidinediones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Dipeptidyl Peptidase-4 (DPP-4) inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Glucagon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
5. Global Hypoglycemic Drugs Market, By Route of Administration, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
6. Global Hypoglycemic Drugs Market, By Distribution Channel, 2026-2033 (USD Mn)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
7. Global Hypoglycemic Drugs Market, By Region, 2026 - 2033 (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country, 2026-2033 (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
- Market Size and Forecast, By Country/ Region, 2026-2033 (USD Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Company Profiles
- Eli Lilly & Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Boehringer Ingelheim GmbH
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Vistin Pharma AS
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Janssen Pharmaceuticals NV
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Astellas Pharma Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AstraZeneca plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Novo Nordisk A/S
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Teva Pharmaceutical Pvt. Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Analyst Views
- Eli Lilly & Company
9. Section
- References
- Research Methodology
- About Us and Sales Contact
